Review decision - December 2020
Decision that the existing guidance remains unchanged
We would like to update you on the decision made regarding the review of the existing guidance on TA440; Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine.
There is no new evidence to address the key uncertainties identified in the original appraisal. The relative effectiveness of pegylated liposomal irinotecan compared with current practice was highly uncertain in the original appraisal. Head-to-head randomised trial data was needed, or further evidence to inform an indirect treatment comparison. The review did not find evidence to resolve these issues.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA440 will not be updated at this time.
This page was last updated: